Law360, New York (January 06, 2011, 7:37 PM ET) -- The Second Circuit on Thursday shot down nonprofit group CareToLive's suit attempting to ferret out additional information from the U.S. Food and Drug Administration about its initial decision not to approve prostate cancer immunotherapy treatment Provenge.
A three-judge panel for the U.S. Court of Appeals for the Second Circuit ruled that a district court did not abuse its discretion when it granted the FDA summary judgment and denied CareToLive leave to conduct discovery.
CareToLive, which focuses on treatment for prostate cancer patients, first launched the suit...
FDA Doesn't Have To Release Provenge Docs: 2nd Circ.
To view the full article, take a free trial now.
